NCT05380414Recruiting
Profiling Program of Advanced/Metastatic Pancreatic Cancer Patients
A Single-center, Prospective Profiling Program of Advanced/Metastatic Pancreatic Cancer Patients
Source: ClinicalTrials.gov · Last updated 31 Mar 2026
Brief summary (registry, in English)
The proposal is to implement a molecular screening program for advanced/metastatic pancreatic cancer patients before the initiation of 1st line treatment in order to allow a better selection of patients for rationale personalized medicine with targeted agents and/or combination involving a chemotherapy backbone.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 750 (estimated)
- First submitted
- 10 May 2022
- Start date
- 1 Jul 2022
- Primary completion date
- 1 Sept 2027
- Lead sponsor
- Centre Leon Berard
- Diseases
- Pancreatic cancer
- NCT number
- NCT05380414
What you commit to
- Study type: Interventional
- Planned participants: 750
- From 1 Jul 2022 to the primary completion date, 1 Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Curative therapy available
Other illness
- Any condition contraindicated with blood sampling procedures required by the protocol.
- Known additional malignancy that is progressing or requires active treatment. Exceptions include adequately treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer.
Other
- Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure.
Who the study is looking for
- Male or female patient \> 18 years
- metastatic or advanced PDAC
- Patient pretreated with no more than one prior systemic chemotherapy for metastatic/advanced disease (radiotherapy is not counted as a line of therapy).
- Availability of an archival representative FFPE tumor sample from primary tumor (surgery or diagnostic biopsy) and/or from metastatic lesion if metastatic disease at initial diagnosis with associated pathology report from an archival tumor block.
- Life expectancy \> 3 months
- PS score 0 or 1.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Leon Berard Coordinator of this site? Confirm its status | Lyon | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.